Its anti-diabetic affection produced by reducing insulin resistance suppressing oxidative stress in HFD-STZ-induced T2D rats and STZ-NCT-induced T2D rats and suggested that the dose-dependent hypoglycemic activity and potential molecular mechanisms of the oral administration of TMP assessed by calculating the expression levels of phosphorylated PI3K and AKT proteins and mRNA in skeletal muscle, heart and adipose tissue of T2D rats (Rai et al., 2019; Rai et al., 2019). The gene discussed is AKT1; the disease is Insulin resistance.